Cediranib (AZD2171) | 1613

Cediranib (AZD2171) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors. Studies show cediranib to be generally well tolerated as monotherapy at doses of 45 mg/d or less.

Cediranib (AZD2171) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors.

1613 | Cediranib (AZD2171) DataSheet

Alternate Name/Synonyms: AZD2171, Recentin

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 288383-20-0

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₅H₂₇FN₄O₃

Molecular Weight: 450.51

Cell-Permeable?: Yes

Purity: ≥98%

Solubilities: DMSO (10 mM)

Handling: Protect from air and moisture

Country of Origin: USA

Tag Line: A VEGFR and c-Kit kinase inhibitor

MDL Number: MFCD09954115

PubChem CID: 9933475

SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5

InChi: InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22 (31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H, 3-5,8-11H2,1-2H3

InChi Key: XXJWYDDUDKYVKI-UHFFFAOYSA-N